Botulinum Toxin Brands: How Botox, Dysport, Xeomin and Azzalure Differ

Several branded botulinum toxin type A products are available internationally, and while they share a common mechanism of action, they are manufactured differently and are not interchangeable on a unit-for-unit basis. Knowing the main brands and how they are positioned is useful for reading the wider literature accurately and understanding what a patient means when they ask for a specific name by default.

The Main Brands on the Market

• Botox (onabotulinumtoxinA), manufactured by Allergan, was the original commercially available product and remains the most widely recognised name.
• Dysport (abobotulinumtoxinA), manufactured by Ipsen, is another long-established option, with a different formulation and dosing-unit system from Botox.
• Xeomin / Bocouture (incobotulinumtoxinA), manufactured by Merz, is notable for a purification process that removes the complexing proteins present in some other formulations.
• Azzalure, manufactured by Galderma, is essentially the aesthetic-indicated formulation of the same molecule marketed as Dysport, sold under a different brand name for cosmetic use in some markets.

Why Brand Names Multiply for a Similar Molecule

Manufacturers often license the same underlying formulation under different brand names depending on the indication or market — a therapeutic-use brand and an aesthetic-use brand can be the same product marketed differently. This is why the same underlying formulation can appear under two names depending on the region or the intended use, and it is worth checking which name applies to which indication in your own market rather than assuming.

Units Are Not Interchangeable Between Brands

Dosing conventions, expressed in units, are brand-specific and are not directly convertible one-to-one between products. A unit of one brand does not equal a unit of another, even though the products act on the same biological target. This distinction is essential when reading published dosing literature that spans more than one brand, and confusing the two is a common and consequential error.

What Determines Which Brand a Clinic Stocks

Which brand, or brands, a clinic carries is typically decided by regulatory approval status in that country, supplier relationships, and a clinician's own training and familiarity with a given formulation's handling characteristics — rather than any one brand being universally superior to the others.

The Takeaway

The major botulinum toxin brands share a common target at the neuromuscular junction, but differ in manufacturing process, purification and dosing conventions. Treating them as interchangeable by unit count is a common mistake; understanding the brand landscape is a basic literacy point for anyone working in injectable aesthetics.

For the injection consumables used across neuromodulator and filler treatments, browse the needles and syringes range.